Arnold Willemsen
A5060010792- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Influenza Virus Research Studies
- Respiratory viral infections research
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Hormonal and reproductive studies
- Estrogen and related hormone effects
- Hematopoietic Stem Cell Transplantation
- Sexual Differentiation and Disorders
- Virology and Viral Diseases
- Growth Hormone and Insulin-like Growth Factors
GGD Amsterdam
2024
Charles R. Drew University of Medicine and Science
2005
In Europe, the combination of plerixafor + granulocyte colony-stimulating factor is approved for mobilization hematopoietic stem cells autologous transplantation in patients with lymphoma and myeloma whose mobilize poorly. The purpose this study was to further assess safety efficacy front-line European or myeloma. multicenter, open label, single-arm study, received (10 μg/kg/day) subcutaneously 4 days; on evening day they were given (0.24 mg/kg) subcutaneously. Patients underwent apheresis 5...
Objective: We compared the effectiveness of a biweekly regimen 150 mg nandrolone with placebo in HIV-infected men mild to moderate weight loss and contrasted its effects against Food Drug Administration-approved recombinant human (rh)GH.
Invasive meningococcal disease has its highest incidence in infants. Co-administration of serogroup B (4CMenB) and quadrivalent conjugate (MenACWY-CRM) vaccines could protect against 5 clinically-relevant serogroups. This phase 3b, open, multicenter study (NCT02106390), conducted Mexico Argentina, enrolled randomized (1:1:1) 750 healthy infants to receive either 4CMenB co-administered with MenACWY-CRM (4CMenB/MenACWY group), (4CMenB or alone (MenACWY group) at ages 3, 5, 7 13 months....
Meningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel 110 strains.
Neisseria meningitidis is associated with high mortality and morbidity in infants children worldwide. This phase 3 study (NCT02173704) evaluated safety immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered routine vaccines Taiwanese infants. In total, 225 healthy were randomized (2 : 1 ) to receive 4CMenB (4CMenB+Routine) or only (Routine group) at 2, 4, 6 12 months age. Routine diphtheria-tetanus-acellular pertussis-inactivated...
No data are currently available on immunogenicity of higher-valent pneumococcal conjugate vaccines when co-administered with a 4-component meningococcal serogroup B vaccine (4CMenB). Post-hoc analysis non-typeable Haemophilus influenzae protein D (PHiD-CV) 4CMenB (2 + 1 schedule) and/or CRM-conjugated C (MenC-CRM) in trial assessing reduced schedules and co-administration MenC-CRM (NCT01339923). Infants were randomized to receive (Group 1) or 2) at 3, 5, 12 months (M) age. Both groups...